急性脑梗死阿替普酶静脉溶栓后血管再闭塞应用低分子肝素钙的价值

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (628 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study application value of the low molecular weight heparin calcium in re-occlusion patients in the process of thrombolysis with alteplase. Methods Forty-four patients with acute cerebral infarction admitted into this hospital in 2010-2014 were divided into observation group(n=23) and control groups(n=21).The former received low molecular weight heparin calcium combined with alteplase.The outcome scores were evaluated according to the National Institute of Heath Stroke Scale(NIHSS) before treatment and 1 d, 14 d after thrombolysis,the modified Rankin Scale (mRS) score after thrombolysis 90 d were observed,and the mortality, hemorrhagic transformation as the safety indicators were evaluated. Results There were significant differences in efficacy outcome rate (78.3%, 42.9%, respectively) between the two groups at 14 days (P<0.05). There were no significant differences between the two groups in the incidence of mortality and cerebral hemorrhage (symptomatic and non-symptomatic intracerebral hemorrhage) at 90 d. There were significant differences between the two groups at 90 d in mRS score (2.00±1.51, 3.10±1.76, respectively,P<0.05). Conclusions The treatment of the low molecular weight heparin calcium combined with alteplase in patients with aggravation of signs and symptoms in the process of thrombolysis can improve neurological function with satisfactory results.

Key words： acute cerebral infarction alteplase thrombolysis re-occlusion low molecular weight heparin calcium

Received: 20 February 2015

ZTFLH:

R743.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Lixun
	GENG Ruihui
	LU Xuesheng
	LI Keliang
	DING Sujv

Cite this article:

ZHU Lixun,GENG Ruihui,LU Xuesheng等. Application value of low molecular weight heparin calcium in treatment of re-occlusion patients in process of thrombolysis with alteplase[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(6): 555-557.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I6/555

[3]	Furie K L, Kasner S E, Adams R J, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [J]. Stroke, 2011, 42(1):227-276.
[1]	中华医学会神经病学分会脑血管病学组指南协作组. 2010 中国急性缺血性卒中诊治指南[J]. 中华神经科杂志,2010,43(2):146-154.
[4]	Fulgham J R, Ingall T J, Stead L G, et al. Management of acute ischemic stroke [J]. Mayo Clin Proc, 2004,79(11):1459-1469.
[5]	Heo J H, Lee K Y, Kim S H, et al. Immediate re-occlusion following a successful thrombolysis in acute stroke: a pilot study [J]. Neurology, 2003,60(10):1684-1687.
[2]	Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke [J]. New England Journal of Medicine, 2008,359(13):1317-1329.
[6]	Grotta J C, Welch K M A, Fagan S C, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial [J]. Stroke, 2001,32(3):661-668.
[3]	Furie K L, Kasner S E, Adams R J, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [J]. Stroke, 2011, 42(1):227-276.
[4]	Fulgham J R, Ingall T J, Stead L G, et al. Management of acute ischemic stroke [J]. Mayo Clin Proc, 2004,79(11):1459-1469.
[7]	Adams H P, Del Zoppo G, Alberts M J, et al. Guidelines for the Early Management of Adults With Ischemic Stroke A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists[J]. Circulation, 2007,115(20):e478-e534.
[5]	Heo J H, Lee K Y, Kim S H, et al. Immediate re-occlusion following a successful thrombolysis in acute stroke: a pilot study [J]. Neurology, 2003,60(10):1684-1687.
[6]	Grotta J C, Welch K M A, Fagan S C, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial [J]. Stroke, 2001,32(3):661-668.
[8]	Toyoda K, Okada Y, Kobayashi S. Early recurrence of ischemic stroke in Japanese patients: the Japan standard stroke registry study [J]. Cerebrov Dis, 2006,24(2-3):289-295.
[9]	Alexandrov A V, Grotta J C. Arterial re-occlusion in stroke patients treated with intravenous tissue plasminogen activator[J]. Neurology, 2002,59(6):862-867.
[7]	Adams H P, Del Zoppo G, Alberts M J, et al. Guidelines for the Early Management of Adults With Ischemic Stroke A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists[J]. Circulation, 2007,115(20):e478-e534.
[10]	Straub S, Junghans U, Jovanovic V, et al. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion[J]. Stroke, 2004,35(3):705-709.
[8]	Toyoda K, Okada Y, Kobayashi S. Early recurrence of ischemic stroke in Japanese patients: the Japan standard stroke registry study [J]. Cerebrov Dis, 2006,24(2-3):289-295.
[11]	Lyden P D. Stroke: Haemorrhage risk after thrombolysis—the SEDAN score [J]. Nature Reviews Neurology, 2012,8(5):246-247.
[9]	Alexandrov A V, Grotta J C. Arterial re-occlusion in stroke patients treated with intravenous tissue plasminogen activator[J]. Neurology, 2002,59(6):862-867.
[12]	Group I S T C. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke [J]. Lancet, 1997,349(9065):1569-1581.
[13]	Chen Z M. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group [J]. Lancet, 1997,349(9066):1641-1649.
[10]	Straub S, Junghans U, Jovanovic V, et al. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion[J]. Stroke, 2004,35(3):705-709.
[11]	Lyden P D. Stroke: Haemorrhage risk after thrombolysis—the SEDAN score [J]. Nature Reviews Neurology, 2012,8(5):246-247.
[12]	Group I S T C. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke [J]. Lancet, 1997,349(9065):1569-1581.
[13]	Chen Z M. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group [J]. Lancet, 1997,349(9066):1641-1649.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(2): 147-149.